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Abstract
Background: Pneumocystis jiroveci pneumonia (PCP) is an important opportunistic infection among
immunosuppressed patients, especially in those infected with human immunodeficiency virus (HIV). The clinical
presentation of PCP in immunosuppressed patients have been well-reported in the literature. However, the
clinical importance of PCP manifesting in the setting of an immunorestitution disease (IRD), defined as an acute
symptomatic or paradoxical deterioration of a (presumably) preexisting infection, which is temporally related to
the recovery of the immune system and is due to immunopathological damage associated with the reversal of
immunosuppressive processes, has received relatively little attention until recently.
Case presentation: We aim to better define this unique clinical syndrome by reporting two cases of PCP
manifesting acutely with respiratory failure during reversal of immunosuppression in non-HIV infected patients,
and reviewed the relevant literature. We searched our databases for PCP cases manifesting in the context of IRD
according to our predefined case definition, and reviewed the case notes retrospectively. A comprehensive search
was performed using the Medline database of the National Library of Medicine for similar cases reported
previously in the English literature in October 2003. A total of 28 non-HIV (excluding our present case) and 13
HIV-positive patients with PCP manifesting as immunorestitution disease (IRD) have been reported previously in
the literature. During immunorestitution, a consistent rise in the median CD4 lymphocyte count (28/µL to 125/
µL), with a concomitant fall in the median HIV viral load (5.5 log10 copies/ml to 3.1 log10 copies/ml) was observed
in HIV-positive patients who developed PCP. A similar upsurge in peripheral lymphocyte count was observed in
our patients preceding the development of PCP, as well as in other non-HIV immunosuppressed patients reported
in the literature.
Conclusions: PCP manifesting as IRD may be more common than is generally appreciated. Serial monitoring of
total lymphocyte or CD4 count could serve as a useful adjunct to facilitate the early diagnosis and pre-emptive
treatment of this condition in a wide range of immunosuppressed hosts, especially in the presence of new
pulmonary symptoms and/or radiographic abnormalities compatible with the diagnosis.
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Pneumocystis jiroveci (Pj) (previously known as Pneumo-
cystis carinii f. sp. hominis) was first identified as a patho-
gen in premature infants suffering from interstitial plasma
cell pneumonia in European countries during and after
World War II, occasionally occurring in epidemics [1-3].
Since then Pneumocystis pneumonia (PCP) had only
been reported sporadically in patients with malignancies
and solid organ transplantations until the HIV epidemic
[4]. The incidence of PCP increased significantly after the
emergence of human immunodeficiency virus (HIV)
infection. However, with the identification of CD4 T lym-
phocyte depletion as an independent risk factor for the
development of PCP [5], widespread use of antimicrobial
prophylaxis [4], and the introduction of highly active
antiretroviral therapy (HAART), there has been a steady
decline in the incidence of PCP among HIV-infected
patients [7,8].
Nevertheless, with the rising number of patients receiving
immunosuppressive therapies for malignancies, solid
organ transplantations and autoimmune diseases, PCP
has been increasingly recognized in non-HIV immuno-
suppressed hosts [9-15]. For instance, PCP occurs in 3.4%
to 43% of solid organ transplant recipients [16], and it is
particularly prevalent among those patients who are put
on long-term steroids. In a non-HIV immunosuppressed
cohort with PCP, the use of steroids was found to be a
contributing factor in 87% of patients [17]. In another
similar cohort of immunosuppressed patients, steroids
had been administered systemically in 90.5% within one
month before the diagnosis of PCP. Although a median
daily dose equivalent to 30 mg of prednisone was admin-
istered in most of these patients prior to the development
of PCP, up to 25% had received as little as 16 mg of pred-
nisone daily [18]. Interestingly, PCP has also been
reported in patients with endogenous steroid excess due
to Cushing's disease [19,20].
Paradoxically, the clinical symptoms of PCP were often
unmasked in HIV-negative immunosuppressed patients
during the reversal of immunosuppression, often at the
time when the dose of steroids was tapered [11,17,21-24],
or when the endogenous steroid production was reduced
[25-27]. However, serial changes in the absolute lym-
phocyte count before and during reversal of immunosup-
pression were not mentioned in these patients. Recently,
paradoxical worsening of clinical symptoms and signs of
PCP after initiation of HAART has also been reported in
HIV-positive patients [28-31]. The onset of clinical deteri-
oration was associated with an upsurge in the CD4 lym-
phocyte count and a reduction in the HIV viral load [28-
31]. Tissue damage is thought to occur as a result of
immune reconstitution in HIV-positive patients. Here, we
report two cases and review the literature on this topic
from the perspective of immunorestitution disease.
Case presentation
Case 1
This is a fifty-one year old female patient with history of
diabetes mellitus and systemic lupus erythematoses (SLE)
complicated by lupus nephritis. Although we have
included her case in our previous publication [32], we
have not reported her clinical details at that time. She was
put on prednisolone 30 mg and azathioprine 100 mg
daily since end of June and mid-July 2002, respectively.
She was admitted to Queen Mary Hospital on 11th August
2002 for investigation of jaundice. Investigations revealed
deranged liver function tests with cholestatic pattern. A
diagnosis of drug-induced hepatotoxicity was entertained,
and azathioprine was stopped after admission. As her
autoimmune disease was under control, her steroid dos-
age was reduced from 25 mg to 15 mg daily within the
next 14 days. Her CXR taken on admission was normal.
Soon after her immunosuppressive therapy was tapered,
she developed fever and non-productive cough. A repeat
CXR performed on 9th Sept revealed new infiltrate over the
left mid-zone, suggestive of pneumonia. She was started
on intravenous ceftazidime 1 gram eight hourly and oral
clarithromycin 500 mg twice daily. Serial CXR performed
three days later showed increasing bilateral pulmonary
infiltrates and worsening hypoxemia. There was an
upsurge of total lymphocyte count from 0.7 × 109/L (total
white cell count 7.2 × 109/L) at the time of admission to
5.6 × 109/L (total white cell count 10.8 × 109/L) at the
time of clinical deterioration. Bronchoscopy with trans-
bronchial biopsy performed on the same day revealed
Pneumocystitis jiroveci by methenamine sliver stain.
Workup for other opportunistic pathogens including
cytomegalovirus and aspergillus was negative. She was
commenced on intravenous pentamidine (4 mg/kg/day)
and corticosteroids for severe PCP infection. Despite
active treatment she developed progressive respiratory
failure and required admission to intensive care unit. She
subsequently recovered after a stormy hospital course,
and upon discharge from hospital, her total lymphocyte
count had returned to her baseline of 0.86 × 109/L.
Case 2
A thirty-three year old gentleman initially presented to
Prince of Wales Hospital with a diagnosis of SLE/dermat-
omyositis overlap syndrome. He was treated with steroid
and hydroxychloroquine 200 mg twice daily since 1997.
He had a flare up of disease in May 1998 with active vas-
culitis and myositis, for which he was put on pred-
nisolone and azthioprine 50 mg and 100 mg daily
respectively. Upon reassessment one month later, diseasePage 2 of 8
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nisolone was reduced to 45 mg daily.
Twelve day after reducing the immunosuppressive regi-
men, he was admitted to hospital for treatment of left but-
tock abscess. The CXR taken on admission was
unremarkable. An aspirate of the pus from the lesion grew
methicillin-sensitive staphylococcus aureus; he was treated
with cloxacillin 1 g intravenously every 6 hourly, together
with incision and drainage of the buttock abscess. In view
of the underlying active pyogenic infection, the steroid
dosage was rapidly tapered from 45 mg to 15 mg daily
within the next four days. However, he was noted to have
persistent fever associated with mild unproductive cough.
A repeat chest radiograph showed new infiltrates over the
right upper and left lower zones, and he was empirically
treated with intravenous ceftazidime 1 gram every 8
hours, cloxacillin 1 gram every 6 hours and netimicin 100
mg every 8 hours. As there was no clinical response after 5
days of treatment, bronchoscopy and bronchoalveolar
lavage (BAL) was performed, which was positive for Pneu-
mocystis jiroveci. Investigation for the presence of co-exist-
ing opportunistic pathogens such as cytomegalovirus and
aspergillus was negative. On the day after bronchoscopy,
he was commenced on intravenous cotrimoxazole 1.3
grams every 6 hours. He remained stable initially with
fever on downward trend. However, on the 3rd day of
treatment, he developed sudden desaturation with resur-
gence of high fever, and required supplemental oxygen
therapy. Repeat chest radiograph showed increased peri-
hilar hazziness in both lung fields. There was also an
upsurge of total lymphocyte count from 0.6 × 109/L (total
white cell count 11.2 × 109/L) on admission, to 1.3 × 109/
L (total white cell count 10.4 × 109/L) at the time of clin-
ical deterioration. He was treated with high dose pred-
nisolone (80 mg daily), and his condition improved
promptly afterwards. He was subsequently discharged,
and on follow up at the clinic one month later, his total
lymphocyte count had returned to his baseline level of 0.6
× 109/L.
Immunorestitution disease (IRD) has been described in
both HIV and non-HIV immunosuppressed hosts previ-
ously [27-31]. In the setting of PCP, it is defined as an
acute symptomatic presentation of the disease that is
related temporally to the recovery of the immune system,
associated with reversal of immunosuppressive processes
such as reduction in the dosage of corticosteroids and/or
cytotoxic agents or a reduction of HIV viral load due to
HAART, which results in the development of immun-
opathological damage. The preexisting microbial infec-
tion could be either asymptomatic or mildly
symptomatic. Using this case definition, we attempted to
review the English literature for other reported cases of
PCP manifesting as IRD. The English-language literature
(1966 – 2003) was searched in the Medline database of
the National Library of Medicine in October 2003. The
keywords "Pneumocystis carinii", "Pneumocystis jiroveci",
"HIV", immunosuppression", "immunosuppressive",
"steroid", and "corticosteroid" were used to select cases.
All the case reports and case series with clinical details
were included in this study if they fulfilled the above def-
inition of IRD. When appropriate, the cited bibliographies
were also retrieved for further analysis. As for statistical
analysis, we used the Wilcoxon Signed Rank test, a non-
parametric test for comparing paired samples, to analyze
the serial changes in lymphocyte counts and HIV viral
loads before and during the development of IRD. A two-
tailed p-value of less than 0.05 was considered significant.
All statistical analyses were performed using SPSS version
11.5 for Windows.
Including our present case, a total of 29 cases of PCP in
non-HIV immunosuppressed hosts fulfilling our defini-
tion of IRD have been reported in the literature (table 1)
[22-27,32]. There were altogether 13 males and 8 females,
with a median age of 38 years (range 2 to 75 years). The
age and sex were not mentioned in 8 cases. Their underly-
ing immunosuppressive conditions included solid organ
tumours (13 cases), haematological diseases (8), autoim-
mune diseases (4), endogenous Cushing's disease (3),
and a solid organ transplant recipient (1). All patients had
received steroids or had excessive endogenous steroid pro-
duction, whereas 18 (62.1%) of them had concomitant
cytotoxic therapy for the underlying diseases. The median
duration between steroid tapering and clinical manifesta-
tions of PCP was 21 days (range 1 to 83 days). Steroids
were completely withdrawn at a median of 7.5 days
(range 1 to 21 days) before the onset of symptoms in eight
patients. Serial lymphocyte counts were only available in
eight patients. An upsurge of the absolute lymphocyte
counts was observed from the time of reduction of immu-
nosuppression (median 300/µL, range 290 to 600/µL at
baseline) to the time of occurrence of IRD (median 1200/
µL, range 600 to 5620/µL); the median increase in total
lymphocyte count was 800/µL, with a range of 300 to
4880/µL. Comparing the lymphocyte counts before and
after reversal of immunosuppressive therapy, the differ-
ence was statistically significant (Wilcoxon Signed Rank
Test for paired samples; p = 0.012). In addition to our
patient, reintroduction or increasing doses of steroids
were required in 7 (53.8%) of 13 patients in the acute
management of PCP in the literature, at the time when
they developed clinical deterioration during antimicro-
bial therapy [24-27]. Seven (53.8%) of 13 cases had respi-
ratory failure requiring mechanical ventilation. Among
these 29 cases, 13 (44.8%) subsequently died of PCP.
Among HIV-positive patients, 13 cases with newly diag-
nosed PCP were reported in the literature, in which IRDPage 3 of 8
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[28-31]. Seven (53.8%) out of 13 cases received steroids as
adjunctive therapy in addition to antimicrobials. HAART
was given in all cases at a median 18 days (range 1 to 35
days) after the initiation of treatment for PCP. During
IRD, recurrence of fever (100%), dyspnoea (100%), and
paradoxical worsening of pulmonary infiltrates (58.3%)
were observed in these patients [28-31]. IRD occurred at a
median of 14 days (range 5 to 17 days) after HAART. An
upsurge of the CD4 lymphocyte count was observed
before (median 28/µL, range 4 to 290/µL) and during IRD
(median 125/µL, range 30 to 564/µL); this was associated
with a concomitant reduction of the median HIV viral
load from 5.5 log10 copies/ml (range 5.0 to 5.9 log10 cop-
ies/ml) to 3.1 log10 copies/ml (range 2.9 to 4.5 log10 cop-
ies/ml) before and during IRD respectively, and the
Table 1: Summary of literature reported cases of HIV-negative immunocompromised patients with PCP manifested as IRD
Case [Ref.] Sex/Age (years) Underlying disease (s) Reduction of IS level 
before symptoms 
onset of IRD
Symptoms & signs at IRD; change of 
lymphocyte count before & during 
IRD (if mentioned)
Treatment, clinical 
progress & outcome
1–7 [22] M/F: 4:3 Median 
age 12, range 2–
25
Acute leukemia in 
remission (4), acute 
leukemia in relapse 
(1), Hodgkin's disease 
(1), embryonal 
carcinoma of testes 
(1)
P ↓ from 100 mg to 
40 mg over 3 weeks in 
1 patients;
In another 6 patients, 
P stopped in a median 
of 10.5 days, range (1–
21 days) before 
symptoms onset
NM Died (5) & survived (2)
8–15 [23] NM Primary brain tumour 
(8)
Dexa ↓ over a median 
of 12.5 days, range (1–
63 days)
Fever (4), nonproductive cough (4), 
productive cough (2), dyspnoea (7), 
chest pain (4); CXR: bilateral 
infiltrates (3), diffuse infiltrates (3), 
focal infiltrates (1), clear (1)
Died (3) & survived (5)
16 [24] M/55 Primary brain tumour 
(glioblastoma 
multiforme)
Dexa ↓ from 16 mg 
qd to 2 mg qd over 8 
weeks
Intermittent fever, nonproductive 
cough, progressive dyspnoea; CXR: 
bilateral interstitial infiltrates; PaO2 
(RA): 51 mmHg
Treated with intravenous 
cotrimoxazole; survived
17 [24] F/74 Primary brain tumour 
(meningioma)
Dexa ↓ from 12 mg 
qd to 4 mg qd over 2 
weeks
Intermittent fever, nonproductive 
cough; CXR: bilateral interstitial 
infiltrates; PaO2 (RA): 45 mmHg
Treated with intravenous 
cotrimoxazole; survived
18 [24] M/50 Primary brain tumour 
(astrocytoma)
Dexa ↓ from 16 mg 
qd to 1 mg qd over 8 
weeks
Fever, nonproductive cough, 
dyspnoea; CXR: bilateral interstitial 
infiltrates; PaO2 (RA): 73 mmHg
Treated with intravenous 
cotrimoxazole; 
mechanical ventilation; 
survived
19 [24] M/75 Primary brain tumour 
(glioblastoma 
multiforme)
Dexa ↓ from 16 mg 
qd to 4 mg qd over 6 
weeks
Fever, nonproductive cough, bloody 
diarrhoea; CXR: clear; PaO2 (RA): 
89 mmHg
Treated with intravenous 
cotrimoxazole; survived
20 [25] M/24 ACTH- producing 
metastatic bronchial 
carcinoid
Serum cortisol ↓ from 
138 pg/ml to 18 pg/ml 
over 54 days
Fever, nonproductive cough, 
weakness, sweats; CXR: bilateral 
fluffy infiltrates; PaO2 (RA): 40 
mmHg
Treated with intravenous 
cotrimoxazole; 
mechanical ventilation; 
died of malignancy
21 [26] F/38 Endogenous Cushing's 
syndrome
Metyrapone 750 mg 
qd added 1 day before 
symptoms onset
Productive cough, dyspnoea; CXR: 
right lower upper lobe infiltrates; 
PaO2 (RA):31 mmHg
Treated with intravenous 
cotrimoxazole; 
mechanical ventilation; 
died
22–28 [32] M/F 4:3 Mean 
(SD) age 53.1 
(13.6)
ITP (2), GN (2), 
bullous pemphigoid 
(1), endogenous 
Cushing's syndrome 
(1), and renal 
transplantation (1)
Reduction of steroid 
but details of tailing 
regimen was not 
mentioned
An upsurge of lymphocyte counts 
from the reduction of 
immunosuppression (median 300/
µL, range 290 to 740/µL) to the 
onset of IRD (median 1500/µL, 
range 600 to 5620/µL)
Treated with steroid as 
anti-PJP therapy in 7 
(100%); mechanical 
ventilation in 6 (85.7%), 
died in 3 (42.9%)
29 M/33 (Our 
patient)
Systemic lupus 
erythematosus/
dermato-myositis 
overlapping syndrome
P ↓ from 45 mg to 15 
mg over 4 days
Fever, dyspnoea; CXR: increased 
perihilar infilitrates; lymphocyte 
count increased from 600 to 1300/
µL
Treated with intravenous 
cotrimoxazole and 
steroid; survived
Note. Aza, azathioprine; CXR, chest radiograph; Dexa, dexamethasone; IRD, immunorestitution disease; ITP, immune thrombocytopenia purpura; 
IS, immunosuppression; GN, glomerulonephritis; P, prednisolone; PCP, Pneumocystis jiroveci pneumonia; RA, room air.Page 4 of 8
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Case [Ref.] 
Sex/Age
CD4 (/µL) & 
HIVRNA 
(log10 copies/
ml) before 
HAART
Therapy of 
PJP & HAART 
regimen
Day of 
HAART after 
initiation of 
PCP 
treatment
Symptoms & signs 
during IRD
Day of 
IRD after 
initiation 
of HAART
Day of 
steroid 
withdrawal 
before the 
onset of IRD
CD4 (/µL) & 
HIVRNA 
(log10 copies/
ml) during 
IRD
Therapy of 
IRD & clinical 
outcome
1 [28] M/37 7 & 5.1 Cotrimoxazol
e & MP; 
zidovudine, 
lamivudine, & 
indinavir
16 days High fever, acute 
respiratory failure; 
CXR: patchy 
alveolar opacities in 
both upper lobes
7 days 7 days 38 & UD Restart cotri-
moxazole & 
stop HAART; 
survived
2 [28] M/47 28 & 5.0 Cotrimoxazol
e & MP, then 
aerosolized 
pentamidine; 
viramune, 
stavudine, & 
didanosine
1 day High fever, acute 
respiratory failure 
requiring intubation; 
CXR: diffuse 
alveolar opacities
17 days 2 days 40 & 4.5 Restart MP & 
stop HAART; 
survived
3 [28] F/50 230 & 5.8 Cotrimoxazol
e & MP; 
zidovudine, 
lamivudine, & 
indinavir
16 days High fever, acute 
respiratory failure; 
CXR: patchy 
alveolar opacities in 
both upper lobes
7 days 7 days 564 & 3.1 Start 
Atovaquone, 
aerosolized 
pentamidine, 
& steroid; 
survived
4–6 [29] 
NM
26 & 5.5 
(median)
Cotrimoxazol
e & high dose 
steroid; NM
15 – 18 days 
(range)
Swinging fever, acute 
respiratory failure, & 
radiological 
deterioration
5 days 
(median); 
3–17 days 
(range)
NM 62 & 2.87 
(median)
Re-
introducing 
high dose 
steroids & 
alternative 
PJP therapy; 
all three 
patients 
survived
7 [30] M/38 4 & 5.5 Atovaquone; 
didanosine, 
efavirenz, 
nelfinavir, & 
stavudine
35 days Fever, cough, 
dyspnoea, & night 
sweats; CXR: 
bilateral mid & lower 
zone airspace 
shadow
14 days NA 125 & 3.6 Intravenous 
pentamidine 
& 
hydrocortiso
ne; survived
8 [30] NM 70 & NM Cotrimoxazol
e; zidovudine
182 & NM Cotrimoxazol
e; survived
9 [30] NM 10 & NM Cotrimoxazol
e; zidovudine
21 days 
(median) 17–
24 days 
(range)
Fever, dyspnoea, 
with or without 
cough
15 days 
(median) 
5–30 days 
(range)
NM 30 & NM Supportive 
therapy
10 [30] NM 216 & NM Cotrimoxazol
e & steroid; 
zidovudine
340 & NM Cotrimoxazol
e & steroid
11 [30] NM 290 & NM Cotrimoxazol
e; zidovudine, 
& didanosine
430 & NM Cotrimoxazol
e
12 [30] NM 60 & NM Cotrimoxazol
e; zidovudine
130 & NM Supportive 
therapy
13 [31] M/
34
46 & > 5.9 Cotrimoxazol
e; zidovudine, 
lamivudine, 
lopinavir-
ritonavir
18 days Recurrent fever, 
chest discomfort, 
cough, & dyspneoa; 
CXR showed diffuse 
bilateral 
reticulonodular 
infiltrates
14 days NA 435 & 4.5 Cotrimoxazol
e (pro-
phylactic 
dose) & 
keeping 
HAART; 
survived
Note. CXR, chest radiograph; HAART, highly active antiretroviral therapy; IRD, immunorestitution disease; MP, methylprednisolone; NA, not 
applicable; NM, not mentioned; PCP, pneumocystis jiroveci pneumoniaPage 5 of 8
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loads before and during IRD reached statistical signifi-
cance (Wilcoxon Signed Rank Test for related samples; p =
0.001 and 0.017, respectively). Antimicrobials, steroids,
or both for PCP were reintroduced for IRD in 4, 1, and 6
cases respectively. Only 2 cases were treated conserva-
tively. One case required mechanical ventilation for severe
respiratory distress. None of the patients died.
PCP manifesting as a form of IRD is not a rare phenome-
non. As shown in our previous study, it happens in 7 out
of 10 (70%) of HIV-negative immunosuppressed hosts
infected with Pj [32]. However, the diagnosis of PCP is
usually delayed in this group of patients because of atypi-
cal presentation. In this clinical setting, PCP manifesting
as IRD often runs an acute and fulminant course, with
nonspecific lesions on chest radiographs, and high abso-
lute lymphocyte counts [32]. In our own reported series,
despite the administration of steroid therapy to suppress
the immunopathological damage, more than 80% of
patients developed acute respiratory failure and required
mechanical ventilation. Patients who developed PCP dur-
ing reversal of immunosuppressive therapy in our series
tended to be older, and this might partially explain the
increased mortality observed in this group [32].
Rapid reduction of immunosuppressive therapy such as
steroids has been implicated as a predisposing factor for
the development of PCP in HIV-negative patients
[11,17,23,24]. In one study, PCP occurred in 79 (70%) of
113 patients during steroid tapering [17]. Another study
suggested that 8 (72.2%) out of 11 episodes of PCP devel-
oped when steroid therapy was tapered [23]. A subse-
quent study also demonstrated that 43% of patients had a
rapid reduction of steroid dosing before the clinical man-
ifestations of PCP [11]. A similar experience was reported
in children, and 17 (89.5%) out of 19 children were diag-
nosed to have PCP during steroid tapering according to a
previous report [21]. Another series revealed that 7 of 11
patients experienced acutely symptomatic PCP when the
dose of steroids was decreased or terminated 5 days to 3
weeks before the diagnosis of PCP [22]. However, all these
cases were not analyzed from a perspective of IRD. Serial
changes of the absolute lymphocyte counts or their sub-
sets were either not noted or reported [11,17,21-24].
Hence we have not included these cases for further analy-
sis in this review.
Among HIV positive patients, PCP manifesting acutely
during the initiation anti-retroviral therapy is a well-rec-
ognized phenomenon. The underlying immunopatholog-
ical nature of this condition, which is reminiscent to IRD
occurring in non-HIV infected patients, has been con-
firmed by histological examination of the lungs and trans-
bronchial biopsy specimens, which demonstrated mixed
inflammatory infiltrates including macrophages, neu-
trophils, lymphocytes, and plasma cells. Almost all infil-
trating lymphocytes found in the tissues were of the T cell
lineage, shown by immunophenotyping to be predomi-
nantly CD4 and CD8 cells [28]. In another study [30], the
BAL fluid obtained from one of six patients with an IRD-
type presentation of PCP was analyzed. Infiltration of pre-
dominantly CD4 and CD8 lymphocytes with the prolifer-
ative marker (Ki67) and perforin-positive cell were seen in
the BAL specimen. Therefore, it is likely that the phagocy-
tosed Pj is presented by alveolar macrophage to T cells,
which trigger the inflammatory response [30].
In our own experience, as well as from the review of pub-
lished literature, it appears that a surge of absolute lym-
phocyte count, especially the CD4 lymphocyte count in
HIV-positive patients, could potentially act as a surrogate
marker for immunopathological damage during IRD in
both HIV-negative and HIV-positive patients. In our
recent publication [32], 7 out of 10 non-HIV immunosup-
pressed patients demonstrated a consistent rise in the
absolute lymphocyte count during tapering of immuno-
suppression prior to the onset of symptomatic PCP. In
this group of patients, the surge in lymphocyte count is
likely the result of withdrawal of lymphocytotoxic immu-
nosuppressants such as corticosteroids. Similarly, a rising
trend of the CD4 lymphocyte count, consistent with
immune reconstitution after HAART, was also observed in
13 HIV-positive cases before and during the development
of symptomatic PCP [28-31]. In fact, an upsurge in the
absolute lymphocyte count has been shown to be a
marker of IRD in our previous publications involving viral
and tuberculous infections [33-36]. However, it must be
emphasized that the number of circulating lymphocytes
may not always correlate with their number in the affected
tissues or their in vivo functional activity. This can be
exemplified by a case of PCP occurring during steroid
withdrawal, in which the lymphocyte counts surged to a
very high level and then rapidly dropped to a low level
within one day. The migration of lymphocytes from the
circulation to tissue might explain this rapid drop in lym-
phocyte count and the resulting immunopathological
damage [27]. In the future, further studies on lymphocyte
subsets and cytokine profiles of susceptible hosts during
the development of IRD should be performed to elucidate
the underlying immunopathological mechanisms behind
this interesting phenomenon.
From the result of this review, it appears that HIV-positive
patients with PCP are at risk of clinical deterioration due
to IRD if HAART therapy is started within 1 to 2 weeks
after the initiation of treatment for PCP (table 2). With a
better understanding of the pathogenetic mechanisms
resulting in IRD, we may be able to prevent the occurrence
of IRD by delaying the initiation of HAART in HIV-posi-Page 6 of 8
(page number not for citation purposes)
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suppressed patients, it is even more important to
recognize the atypical presentations of PCP in the context
of IRD. Since the clinical and/or radiological features
alone may not be sufficient for diagnosis, analysis of serial
changes in lymphocyte counts in patients undergoing a
reduction of immunosuppression can alert the clinician
to the possibility of IRD due to occult pathogens such as
Pj. To prevent IRD in non-HIV immunosuppressed
patients, the use of prophylactic antibiotics against Pj to
reduce the microbial load in selected patients remains an
important issue. Recently, a multi-center study showed
that the CD4 lymphocyte count may be a useful marker to
monitor the risk of development of PCP in non-HIV
immunosuppressed hosts [37], and patients with low
CD4 lymphocyte counts of less than 300 or 400 may
require prophylaxis. In fact, asymptomatic colonization
of Pj has been demonstrated in HIV-negative patients
when the CD4 lymphocyte count was less than 400 [38].
Nested polymerase chain reaction (PCR) identified a sig-
nificant percentage of clinically silent Pj colonization in
20% of non-HIV immunosuppressed patients [39]. There-
fore, early detection of asymptomatic infection of Pj in
blood and respiratory specimens before, and during
intense immunosuppression may enable selection of
cases for pre-emptive treatment of Pj infection in order to
prevent the development of IRD during reversal of immu-
nosuppression [40,41].
Conclusions
PCP occurring in the context of IRD is not a rare phenom-
enon and is likely to be under-reported in the literature. In
this setting, it may be more common for PCP to manifest
acutely with a fulminant clinical course. Clinicians caring
for immunosuppressed patients should be alert to this
unique phenomenon so as to initiate timely and appro-
priate investigations and treatment for their patients.
Serial monitoring of lymphocyte count, or if possible CD4
count, could serve as a useful adjunct to facilitate the diag-
nosis and management of this condition in a wide range
of immunosuppressed hosts, especially in the presence of
new pulmonary symptoms and/or radiographic abnor-
malities compatible with the diagnosis.
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